Positioned to transform the HBV treatment landscape and address the HBV global market opportunity
Portfolio of assets combining multiple technologies aimed at curing HBV
Proven scientific leadership in antiviral and RNAi drug discovery and development
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include the following programs: RNA interference (RNAi) ARB-1467, capsid inhibitor AB-506, HBV DNA destabilizer AB-452 and additional pre-clinical assets.
